The study compared 47,315 adults starting a GLP-1 receptor agonist with 159,066 starting a DPP-4 inhibitor in UK CPRD records from 2007 to 2023. All had type 2 diabetes, a BMI of at least 30 and no prior sleep apnoea. New sleep apnoea was diagnosed at 5.8 per 1,000 person-years on GLP-1 drugs and 5.4 on DPP-4 inhibitors.
Why it is interesting: Trials show reduced apnoea severity; in routine care, GLP-1 drugs brought no fewer new diagnoses.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.